Randomized Phase II Study of Everolimus Alone Versus Everolimus Plus Bevacizumab in Patients with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors
This randomized phase II trial studies how well everolimus and octreotide with or without
bevacizumab works in treating patients with locally advanced or metastatic pancreatic
neuroendocrine tumors that cannot be removed by surgery. Everolimus may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth. Octreotide may interfere
with and slow the growth of tumor cells. Monoclonal antibodies, such as bevacizumab, can
block tumor growth in different ways. Some block the ability of tumor cells to grow and
spread. Others find tumor cells and help kill them or carry tumor-killing substances to
them. Bevacizumab and everolimus also may stop the growth of pancreatic neuroendocrine
tumors by blocking blood flow to the tumor. It is not yet known whether giving everolimus
and octreotide together is more effective with or without bevacizumab in treating pancreatic
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.